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RESEARCH NOTE
Newborn screening for congenital 
hypothyroidism: improvement in short-term 
follow-up by audit and monitoring
Hafsa Majid1* , Sibtain Ahmed1, Imran Siddiqui1, Khadija Humayun2, Hussain Karimi3 and Aysha Habib Khan1
Abstract 
Objective: Newborn screening for congenital hypothyroidism (CH) at our hospital during this study was by meas-
urement of thyroid stimulating hormone (TSH) in serum samples. This audit was conducted over a 2 year period, to 
determine the compliance of reporting of results greater than the screening cutoffs for serum TSH. Gaps of non-com-
pliance were identified, and re-audit was undertaken after the corrective actions were taken.
Results: The critical limit was defined as serum TSH (≥ 20 µIU/ml) following consultation with a pediatric endocri-
nologist. All results above this limit were reported urgently to physicians. During the audit period, 27,407 tests were 
performed, 0.7% had a value of ≥ 20 µIU/ml, of those only 62% were reported to the general paediatrician or neona-
tologist. Reasons for not reporting results included non-availability of contact information, lack of policy awareness by 
technologists, critical results not highlighted on the computer display, and absence of regular monitoring. Corrective 
measures were taken, and re-audit was done. During the re-audit period, a total of 22,985 tests was performed, 0.6% 
had a value of ≥ 20 µIU/ml. Of these, 77% were reported to the general paediatrician or neonatologist. Critical result 
reporting was improved after the audit, and further enhanced the laboratory service of CH screening.
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Introduction
Newborn screening (NBS) programs are considered the 
most extensive preventive medicine system and a vital 
element of public health. The newborns are tested for 
specific disorders, not symptomatically present at the 
time of birth, but if remain untreated can permanently 
impact the health of the baby. The main goal of NBS pro-
grams is to reduce morbidity and mortality and improve 
the health outcomes of newborns. Congenital hypothy-
roidism (CH) is a disorder which if screened for in every 
newborn has a high benefit-to-risk ratio, as a cost-effec-
tive treatment for it is available, it can lead to mental 
retardation if not identified and treated within first few 
weeks of birth.
A key-issue in post-analytical quality is represented by 
the effectiveness of communication of laboratory data, 
particularly communication of critical test results [1]. 
The idea of critical values reporting to physicians was 
first presented by a pathologist, George D. Lundberg, in 
1990. It was felt that communicating abnormally high 
or low laboratory results to the treating physicians can 
help in initiating treatment promptly in life-threatening 
situations. Later, critical values reporting received more 
focused attention by regulatory authorities and agencies, 
including Clinical Laboratory Improvement Amend-
ments of 1988 (CLIA), the Joint Commission (JC) and 
the College of American Pathologists (CAP) [2, 3]. The 
JC National Patient Safety Goals of 2005, amended in 
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timeliness of communication and appropriate actions 
to be taken to improve it. Communicating critical test 
results was also included in patient safety solutions of 
the World Alliance for Patient Safety and World Health 
Organization (WHO) Collaborating Centre for Patient 
Safety Solutions updated in 2008 by the WHO’s Interna-
tional Steering Committee [1, 4].
Laboratories are responsible for testing, reporting criti-
cal results to health care providers, tracking, and improv-
ing the timeliness of reporting [5]. Regulatory authorities 
have put forth safe practice recommendations regarding 
issues related to defining cutoffs for critical results and 
their communication [6]. But there exists no consensus 
on the choice of analytes to be included in the list of criti-
cal results, and clinical laboratories follow both recom-
mendations of scientific societies and clinician’s opinions 
in their institutions [7]. Secondly, there is no consensus 
on cutoffs for routine biochemical analytes. Laboratories 
have to develop their critical results list, define cutoffs, 
do regular audits, update this list and cutoffs according 
to recent guidelines. However, for newborn screening; 
it is recommended that laboratories must determine 
screening cutoffs balancing true and false positives, and 
determine whether a particular result must be reported 
urgently or not urgently, e.g. in CH screening a prob-
able disease result, e.g. over 20 µIU/ml serum would be 
reported urgently, e.g. by phone for recommended action 
of the clinical referral or diagnostic testing.
One screening test that is critical, and requires immedi-
ate clinical action is thyroid-stimulating hormone (TSH), 
performed in neonates for screening and confirmation 
of congenital hypothyroidism (CH). Timely reporting of 
critical values for TSH leads to early treatment, prevent-
ing mental retardation, and is therefore vital to patient 
safety [8]. According to the American Academy of Pedi-
atrics (AAP) guidelines, nearly 10% of infants with con-
firmed CH have TSH values between 20 and 40  mIU/l, 
where conversion factor for TSH from mU/l to µIU/ml 
is 1. It is advisable that in cases with screening test TSH 
concentrations between 20 and 40  µIU/ml, serum-free 
thyroxine (FT4) and repeat TSH should be analyzed [8].
The estimated incidence of CH is 1 in 1000–1600 live 
births in Pakistan, which is higher than the reported inci-
dence in western countries [9, 10]. Guidelines recom-
mend newborn screening for CH should be performed 
between 2 and 4 days of age (48–72 h of birth) by ana-
lyzing TSH (generally on dried blood spot samples), and 
confirmation is done by performing serum TSH and FT4 
[11]. According to AAP and American Thyroid Asso-
ciation (ATA) guidelines for newborn screening and 
therapy for CH newborn screening test results must be 
communicated rapidly back to the general paediatrician 
or neonatologist, who is responsible for the follow-up 
of the newborn, for rapid diagnostic testing and deci-
sion making regarding patient management [12]. Prompt 
reporting of high TSH to the physician will ensure that 
treatment is instituted earlier. So this audit was planned 
to evaluate the compliance of reporting of results greater 
than the screening cutoffs for serum TSH and develop a 
mechanism for short-term follow-up.
Main text
Methods
An audit was conducted at Section of Chemical Pathol-
ogy, Department of Pathology and Microbiology at Aga 
Khan University (AKU). The audit was performed from 
January 2015 to December 2016, followed by gap analy-
sis, implementation of corrective/preventive measures, 
and re-audit in January 2018 to December 2019. At our 
centre, infants are discharged after 48 h, and samples are 
taken just before discharge. Serum TSH is analyzed at 
an automated analyzer ADVIA Centaur (Siemens Diag-
nostics, US) using a chemiluminescence immunoassay 
technique.
The critical result reporting policy for TSH was defined 
in consensus with the clinicians, according to the pub-
lished guidelines for CH screening and diagnosis by AAP 
and ATA. Only one level of TSH, i.e. ≥ 20  µIU/ml, was 
taken as the critical limit. The communication of criti-
cal results procedure was developed as per standards 
defined by the JC and CAP. In the case of inpatients, the 
attending physician was notified while for outside refer-
rals, parents/guardian were communicated the critical 
results. The goal was that 100 per cent of critical results 
should be notified to the concerned person, within 24 h 
of result availability. The results reported, the technolo-
gist informing and parent/physician informed, date and 
time of result reporting, results of TSH, and results read 
back by the person briefed were documented. The results 
which were not critical were reported as per the routine 
laboratory practice.
Data were analyzed by Microsoft Excel 2010. Frequen-
cies of serum TSH tests performed, total critical results 
analyzed and communicated, and reasons for non-com-
munication were investigated.
Results
A total of 27,407 neonates were screened for CH by 
measurement of TSH over 2  years, from 2015 to 2016. 
The Median (Q3 − Q1) age of neonates was 3 days (2–4). 
During the audit period, 0.7% (n = 182) of critical results 
were obtained. The distribution of results appropriately 
reported not reported, and reasons for not reporting are 
shown in Table 1.
During the audit period, only 23% (n = 50) and 17% 
(n = 31) patients were retested for serum TSH (23%) and 
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FT4 (17%), respectively (Table  1). After the audit, the 
project team met to discuss the findings, identify gaps, 
suggest corrective or preventive actions, and devise a 
strategy to implement these actions, shown in Table 2.
Re-audit was performed from January 2018 to Decem-
ber 2019 after the implementation of corrective actions. 
During re-audit period, 22,985 neonates were tested 
for TSH with a median age of 3  days (2–4), and 0.6% 
(n = 139) critical results were obtained. The distribution 
of results reported, patients retested for TSH and FT4 is 
shown in Table 1 which shows improvement in newborns 
retested for TSH (54% vs 23%) and FT4 (43% vs 17%) 
during re-audit period, compared to the audit period.
Discussion
Timely reporting of critical newborn screening results to 
the physicians is crucial for patient + 6 safety and prompt 
initiation of, thyroxine treatment to avoid irreversible 
mental retardation. In the audit period, 0.7% (n = 182) 
patients had critical TSH levels, and only two-thirds of 
these were reported appropriately.
Guidelines also recommend repeating TSH and per-
form FT4 test before initiating CH treatment, so we 
also evaluated the number of repeat TSH, and FT4 per-
formed on patients with critical results. In the present 
study, only 54% of patients were retested for serum TSH, 
and 43% were also tested for serum FT4 during the re-
audit period. Although the number of patients retested 
was increased compared to the audit period, however, it 
was lower than the previously reported audits. An audit 
done by Jones JH on the improvements in screening per-
formance of a Scottish newborn screening program for 
CH, observed that only 82% of the newborns notified of 
high TSH results were resampled for TSH analysis [13]. 
The reason for this difference could be that patients were 
evaluated and tested at another laboratory. Another rea-
son can be that AAP guidelines suggest that every new-
born with serum TSH ≥ 40uIU/ml should immediately 
be initiated on thyroxine treatment and simultaneously 
a repeat sample should be sent for TSH and FT4 analy-
sis for the confirmation of CH. In contrast, only 10% of 
the newborns with serum TSH levels between 20 and 
40 µIU/ml develop confirmed CH. When using a higher 
cutoff, i.e. serum TSH of ≥ 40  µIU/ml for the recall of 
patients, physicians will be more inclined towards retest-
ing for both TSH and FT4 (1 µIU/ml = 1 mU/l).
Gap analysis revealed that the most common rea-
son for non-communication of critical results was non-
availability of the contact information or phone calls 
not received by physicians or patients’ parents/guard-
ians. A similar survey was done in the Italian population 
reporting 7  years’ experience from the screening centre 
Table 1 Findings of audit and re-audit on status of critical results reported to General Pediatricians and Neonatologists
Cut off (µIU/ml) N Results reported/
communicated




Call not received Contact 
not available
Other reason
Audit (Jan 2015–Dec 2016)
n = 27,407
 ≥ 20 182 113 (62%) 17 (9%) 15 (8%) 37 (20%) 50 (23%) 31 (17%)
Re-Audit (Jan 2018–Dec 2019)
n = 22,985
 ≥ 20 139 107 (77%) 8 (6%) 13 (9.4%) 11(8%) 75 (54%) 60 (43%)
Table 2 Gaps identified after audit and correct or preventive actions taken
S# Gap identified Corrective/preventive action taken
1 Unavailability of contacts of mostly outside referral patients Medical receptionists and personnel entering information in the medical 
records were reminded to take patient contact numbers while ordering the 
TSH test
2 Technologists lack critical results reporting policy knowledge A competency assessment of technologists was performed to evaluate knowl-
edge of the critical results reporting policy
Knowledge of the policy was made part of the technologist competency 
assessment form for serum TSH analysis
3 Critical results for TSH were not highlighted on a computer display Critical results of TSH were highlighted and in a different colour in the inte-
grated laboratory management system
4 No monitoring of critical results reported The critical result reported was made a quality indicator with daily monitoring
The goal was set as 100% critical results reported
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in the Lombardy region, Italy. The authors reported that 
the main reason for the non-communication of critical 
results was the relocation of families and lack of con-
tact information. [14]. Another study from the Hospi-
tal for Sick Children in Toronto, Ontario, reported that 
potential reasons for non-communication of results 
were service-related commitments of staff responsible 
for informing and attempting to find ordering physicians 
via informal channels [15]. In the present study, the tech-
nologist responsible for analysis and communicating or 
notifying critical serum TSH results were unable to do 
so due to their high workload. Since there was no moni-
toring system in place, there were delays in reporting the 
critical result.
After the re-audit, the audit team gave the following 
recommendation:
• Communication pathway: a communication path-
way be developed (Fig. 1), as the most common rea-
son for non-communication was the unavailability of 
contact information or phone not received. In a new 
pathway, all results of inpatients with levels ≥ 20 µIU/
ml should be informed to a pediatric endocrine nurse 
available at the endocrine hotline. The nurse notifies 
these results to the patients’ general paediatrician or 
neonatologist, and pediatric endocrinologists. She 
also calls and advice the patient to perform confirma-
tory testing and arranges a follow-up consultation.
• For outside referrals, parents are notified of the 
results and advised to consult the patients’ general 
paediatrician or neonatologist, shown in Fig. 1.
• The collecting laboratory should ensure that contact 
information is included on all serum TSH request 
forms.
• Communications are monitored and audited 
regularly: the audit team further suggested that 
the percentage of subjects notified with serum 
TSH ≥ 20 µIU/ml should be made a quality indicator 
and regularly monitored, as well as audited periodi-
cally.
• Interpretative comments on reports: after the re-
audit period, only 30–55% of patients were retested 
for TSH and FT4. To increase the proportion of 
babies receiving repeat testing, a comment can be 
added to reports of critical TSH levels recommend-




Informed to Parents/Guardian. 
Advised to consult the 
peditrician.
In-patient
Informed to Endocrine hotline
The Endocrine hotline is maintained by a nurse, who is responsible to: 
1. Call parents the same day, inform them of these results & advise them to 
follow up with the primary consultant.
2. Text the parents on their cell phone stating the tests which are required to be 
done: TSH & FT4. 
3. Email the primary consultant and  copying both the endocrinologists about 
the results along with name and Identification number of the patient.
Results <20uIU/ml
Reported as per routine 
practice
Fig. 1 Communication pathway for serum TSH critical results reporting
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low up with paediatrician advised for further man-
agement. This comment was added in all serum TSH 
reports with levels ≥ 20 µIU/ml.
These recommendations put forward by the audit team 
were implemented successfully. Although there were 
some hitches initially, and the pathway defined was fol-
lowed rigorously and monitored regularly.
Conclusion
Newborn screening for congenital hypothyroidism is 
perceived as a very beneficial publish health program. All 
developed countries and many developing countries now 
have established newborn screening programs, at least 
for CH. Laboratory services for CH newborn screening 
can be improved by introducing critical results reporting 
of high TSH levels to the concerned physician. The cur-
rent audit has effectively improved monitoring of post-
analytical practices. Timely informing critical results to 
the physicians is crucial for patient safety, treatment can 
be started on time, and irreversible mental retardation 
can be prevented.
Limitations
• The limitations of this audit were that thyroid hor-
mones and antibody status of mothers of the neo-
nates was not known. Newborns babies born to 
mothers with thyroidal illnesses can present with 
abnormal TSH levels and may be misdiagnosed.
• A single cutoff and not age-related cutoffs were used 
for screening, adopted from AAP guidelines. Along 
with serum TSH, FT4 was not performed with the 
initial sample, and repeat testing results for NTSH of 
all patients were not known.
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